Comment from Fargon Inc.

Summary: Fagron Inc., a company providing active pharmaceutical ingredients and services to compounding pharmacies, requests that the FDA remove L-Ornithine Hydrochloride from the "Nominated Without Adequate Support" list. They argue that the substance is already on the "Under Evaluation" list and that the two entries represent a duplication.